Darsilide plus hormone therapy and double antibody for breast cancer
Part of Cancer, Skin clinical trials.
This trial tests if adding a new drug (darsilide) to standard hormone therapy and two antibodies (trastuzumab and pertuzumab) before surgery can improve outcomes for women with HR-positive, HER2-positive breast cancer that hasn't spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 70 starting treatment for breast cancer.
- Your tumor is stage II or IIIA and has spread to lymph nodes or nearby tissue, but not to distant parts of the body.
- Your cancer is both hormone receptor (HR) positive and HER2 positive.
- You are in good overall health with normal blood counts, liver and kidney function, and heart function.
- You agree to use effective birth control (if still able to have children) during treatment and for 7 months after.
- You have not had other cancer treatments (like chemotherapy, radiation, or immunotherapy) for this or any other cancer (except certain cured skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
This trial tests a new targeted drug (hemay022) combined with an aromatase inhibitor (a type of hormone therapy) for people with advanced breast cancer that is both hormone-receptor-positive and HER2-positive. It may be an option if you've already tried trastuzumab or a similar treatment and it stopped working.
This trial tests a combination of three drugs (dalpiciclib, letrozole, and anlotinib) given before surgery to postmenopausal women with stage II or III HR+/HER2- breast cancer. The goal is to see if this neoadjuvant treatment shrinks tumors and improves outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.